Arrowhead commercializes REDEMPLO (plozasiran) and is building the launch while pursuing label expansion and the SHASTA and YOSEMITE programs. Commercial execution now matters alongside clinical outcomes.. Wait for regular-session confirmation. Wait state: Break $89.59 with confirmed volume.
Arrowhead commercializes REDEMPLO (plozasiran) and is building the launch while pursuing label expansion and the SHASTA and YOSEMITE programs. Commercial execution now matters alongside clinical outcomes.
| Metric | Value | Signal |
|---|---|---|
| Revenue (TTM) | $669.5M | 171.0% YoY |
| EBITDA | N/A | Not meaningful / unavailable |
| Gross Margin | 100.0% | Reported |
| Operating Margin | -226.0% | Loss-making |
| Net Margin | -47.8% | Negative |
| ROE | -55.2% | Capital efficiency |
| Cash | $1.60B | Liquidity |
| Debt | $1.38B | Balance-sheet claim |
| Forward P/E | N/A | No estimate substituted |
| Intrinsic-value model | N/A | Fail-closed: insufficient inputs |
| Value / quality panel | 0 positive / 5 negative / 0 neutral | bearish / confidence 48 |
| Analyst Mean Target | $110.18 | Consensus, not a guarantee |
| Quarter | EPS Actual | EPS Est. | Surprise | Revenue |
|---|---|---|---|---|
| 3Q2025 | $-0.18 | $-0.16 | -14.5% | - |
| 4Q2025 | $0.22 | $-0.37 | 159.9% | - |
| 1Q2026 | $-0.93 | $-1.11 | 16.0% | - |
| 2Q2026 | $-1.36 | $-1.23 | -10.4% | - |
2/4 captured quarters beat estimates — Next: 2026-11-24T20:00:00Z
No structured transaction table was captured; aggregate counts are not used.
| Series | Type | Strike | Shares | Exp. | Dilution | Status |
|---|---|---|---|---|---|---|
| January 2026 | Pre-funded | N/A | 1.550M | N/A | Issued in the 2026 financing | Outstanding |
| Legacy | Outstanding warrants | N/A | 917,441 | N/A | Legacy overhang disclosed in the 10-Q | Outstanding |
Authorized: $500M program | Used: $76.1M gross through nine months | Remaining: Verify the latest 10-Q before entry
A $500M ATM remains relevant after $76.1M of gross issuance. January financing raised $230M and included pre-funded warrants; $700M of 0% convertible notes mature in 2032.
Official filings were reviewed through 2026-08-28; the table lists the decision-relevant documents rather than every routine filing. The C+ grade describes the full dossier; the trade state (wait) is a separate timing decision.
| Date | Form | Accession | What the filing changes |
|---|---|---|---|
| 2026-08-04 | 10-Q | 0000879407-26-000057 | Confirms $1.60B of liquidity, ATM usage and commercial/clinical spending. |
| 2026-01-09 | 424B5 | 0001193125-26-007968 | Documents the January equity and pre-funded-warrant financing. |
| 2025-12-11 | S-3ASR | 0001193125-25-314755 | Establishes the shelf and ATM capacity. |
| 2026-01-09 | 424B5 | 0001193125-26-007962 | Documents the $700M 0% convertible notes due 2032. |
Current snapshot only; no acceleration claim without a comparable historical series.
Unusual Activity: No unusual activity confirmed
| RSI (14) | 56.2 |
| EMA 20 | $87.04 |
| EMA 50 | $83.61 |
| EMA 200 | $66.68 |
| MACD | 1.526 |
| Signal | 1.729 |
| ATR (14) | $3.20 |
| Wyckoff | Transitional |
Wait for regular-session confirmation. Required confirmation: Break $89.59 with confirmed volume. Available moving averages are shown with their provider type.
| Indicator | Value | Signal |
|---|---|---|
| Market regime | Risk-on 0.79 | Trend support, not a timing trigger |
| VIX | 14.51 | Low current protection price |
Regime: risk-on
The broad regime supports long setups, but rates and ticker-specific confirmation override the label.
Dilution: high; beta: 1.29; insider signal: unavailable.
A precise stop does not make a setup valid. Entry location, normal volatility, event risk and reachable resistance decide whether the risk is paid.
No directional flow claim is made when detailed, aligned flow data is unavailable.
Wait for regular-session confirmation. Monitor break $89.59 with confirmed volume; no market order and no chase outside the zone.
Wait for confirmation and preserve the invalidation.
This analysis is provided for informational and educational purposes only. It does not constitute financial advice, investment recommendation, or solicitation to buy or sell any security.
Past performance is not indicative of future results. All investments involve risk, including the possible loss of principal. Always conduct your own research and consult a licensed financial advisor before making investment decisions.
Data comes from point-in-time market snapshots, company filings, Yahoo Finance, SEC EDGAR, and public market data. Accuracy is not guaranteed.
Social Radar
Pump & Dump Score: 1/6
Clean